IFNK Antibody

Code: CSB-PA889172ZA01HU

Rate （N/A）
Review （0）

Size:

0.1ml

0.1ml1ml

Pls inquire

Quantity:

Species Reactivity: Homo sapiens

Raised in: Rabbit

Application: ELISA, WB (ensure identification of antigen)

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q9P0W0

Target Names

IFNK

Alternative Names

Interferon kappa (IFN-kappa), IFNK

Raised in

Rabbit

Species Reactivity

Homo sapiens

Immunogen

Recombinant Homo sapiens IFNK protein

Conjugate

Non-conjugate

Isotype

IgG

Purification Method

Antigen Affinity Purified

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Tested Applications

ELISA, WB (ensure identification of antigen)

Lead Time

Made-to-order (12-14 weeks)
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Value-added Deliverables

① 200ug * antigen (positive control);
② 1ml * Pre-immune serum (negative control);

Quality Guarantee

① Antibody purity can be guaranteed above 90% by SDS-PAGE detection;
② ELISA titer can be guaranteed 1: 64,000;
③ WB validation with antigen can be guaranteed positive;

Datasheet & COA

Antibody FAQs

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

May play a role in the regulation of immune cell function. Cytokine that imparts cellular protection against viral infection in a species-specific manner. Activates the interferon-stimulated response element signaling pathway. It is able to directly modulate cytokine release from monocytes and dendritic cells. Binds heparin.

Gene References into Functions

investigation of common variable immunodeficiency (CVID) from 2 German families; report on the occurrence of a common and one novel truncating IFNK mutation in cases with CVID; the frequency distribution of c.30_31insTGTT in cases and controls as well as the observed segregation patterns in CVID families exclude IFNK mutations as major risk factor in CVID PMID:28324805
These results suggest that high-risk human papillomavirus 31 target interferon kappa to prevent Sp100 expression and identify Sp100 as an interferon-stimulated gene with anti-human papillomavirus activity. PMID:26491169
This study demonstrates that E2 proteins of high risk human papillomavirus reduce STING and IFN-kappa transcription. PMID:24614210
The viral E6 and E7 oncogenes are sufficient for interferon-kappa repression, with E6 being mainly responsible. PMID:21849431
IFN-kappa is down-regulated in cervical keratinocytes harboring HPV, which may be a contributing factor in the progression of a cervical lesion PMID:20479716
Studied IFNK single nucleotide polymorphisms in 3982 Systemic lupus erythematosus cases and 4275 controls. PMID:20706608
IFN-kappa is able to directly modulate cytokine release from monocytes and dendritic cells, inhibit inducible IL-12 release from monocytes, and bind strongly to heparin. PMID:12391192
This is the first report showing an epigenetic silencing of type I IFN after HPV16 oncogene expression PMID:19887612